This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
BackgroundThe renal sympathetic nervous system modulates systemic bloodpressure, cardiac performance, and renal function. Pathological increases in renal sympathetic nerve activity contribute to the pathogenesis of heart failure with preservedejectionfraction (HFpEF).We
BACKGROUND:Obesity and adiposity are associated with an increased risk of heart failure with preservedejectionfraction (HFpEF); yet, specific underlying mechanisms remain unclear. Fasting blood samples collected at the time of the cardiopulmonary exercise test were used to assay obesity-related biomarkers.
Can you please explain the concept of an obesity paradox? Salvatore Carbone, PhD: First, I’d like to point out that obesity is a major risk factor for cardiometabolic disease. 2, 3] This association is more pronounced for those with class I obesity, which is a body mass index (BMI) between 30-35 kg/m2.
Intro:Drug Development for Heart failure with PreservedEjectionFraction (HFpEF) is a major challenge facing cardiovascular research due to its complex pathophysiology and existence of comorbidities, leading to recognize distinct HFpEF phenogroups. l) for 8 weeks. in HFD/L-NAME vs E/A=1.4 ± 0.02
ET Murphy Ballroom 4 Comparison of an "Inclisiran First" Strategy with Usual Care in Patients With Atherosclerotic Cardiovascular Disease: Results From the VICTORION-INITIATE Randomized Trial Targeting Weight Loss to Personalize the Prevention of Type 2 Diabetes Once-weekly Semaglutide in Patients with Heart Failure With PreservedEjectionFraction, (..)
Getty Images milla1cf Wed, 06/26/2024 - 18:59 June 26, 2024 — Semaglutide , a medication initially developed for type 2 diabetes and obesity, significantly improves symptoms in men and women with a common type of heart failure that has had few therapeutic options. The study analyzed the effects of semaglutide 2.4
BackgroundCardiometabolic comorbidities such as obesity, diabetes, and hypertension are highly prevalent in heart failure (HF). Severely uncontrolled comorbidities were defined as systolic bloodpressure 160 mm Hg, hemoglobin A1c 8%, and body mass index 35 kg/m2. Journal of the American Heart Association, Ahead of Print.
42% of adults are considered obese , increasing their risk of diabetes, hypertension, and cardiovascular issues. Key Takeaways: Natriuretic Peptides : Useful for diagnosing and monitoring heart failure, particularly HFrEF, but challenging to interpret in patients with obesity due to peptide deficiency. In the U.S.,
Heart Failure Management : The FINEARTS-HF trial focused on the efficacy of finerenone, an aldosterone antagonist, in reducing heart failure hospitalizations and cardiovascular mortality among patients with preservedejectionfraction (HFpEF). Eckel, MD, FAHA, FACC at the 19th Annual CMHC.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content